This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Eli Lilly Meets Estimates as Revenue Climbs 9%

NEW YORK ( TheStreet) -- Drugmaker Eli Lilly (LLY - Get Report) posted third-quarter adjusted earnings of $1.25 million, or $1.13 a share, in line with analysts' estimates.

Reported net income in the quarter was $1.11 a share vs. $1.18 a share a year ago.

Revenue for the third quarter was better than expected, up 9% to $6.15 billion from $5.65 billion in a year ago. A consensus of analysts anticipated revenue of $6.06 billion.

The maker of Cymbalta and Cialis also sharpened earnings guidance for the full year to a range of $3.89 to $3.94 a share from previous guidance of $3.85 to $3.95 a share. The company pointed to health care reform measures and expiring patent on Zyprexa as important drags on growth. Offsetting these will be increasing sales of Alimta, Cialis, Cymbalta, Effient, Humalog and animal health products.

Follow TheStreet on Twitter and become a fan on Facebook.

Global sales of Zyprexa fell 3% to $1.18 billion, while sales of Cymbalta rose 29% to $1.07 billion.

-- Written by Carlton Wilkinson.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
LLY $71.58 -1.13%
AAPL $130.28 0.47%
FB $81.53 -1.07%
GOOG $565.06 3.30%
TSLA $218.42 -0.08%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs